23 requirements of a leading Carbohydrate CDMO

Carbo CDMO?

Carbohydrates look familiar because biology uses them everywhere. They form the surfaces of cells, the scaffolding of tissues, the recognition patterns of the immune system and the structural backbone of countless natural products. That ubiquity can create a false sense of simplicity.

Manufacturing them reproducibly is another matter entirely. A compact structural drawing may conceal differences in anomeric configuration, linkage position, branching, substitution, acetylation, phosphorylation, sulphation, charge, conformation, reducing-end chemistry, chain length and molecular-weight distribution. Any one of those differences can alter biological activity, immunogenicity, viscosity, clearance, conjugation efficiency, stability or analytical behaviour.

This is why the choice of a carbohydrate CDMO carries unusual weight. The partner must be able to see, control and prove the structural features that actually define the product—features that remain invisible on a simple formula or a bulk identity test.

That complexity makes the selection of a carbohydrate cdmo more demanding than finding a supplier with a fermenter, synthesis laboratory or chromatography suite. The partner must connect carbohydrate chemistry, enzymology, microbial production, purification, structural characterisation, bioconjugation, formulation, quality systems and commercial engineering.

The product class is equally broad. It includes defined oligosaccharides, bacterial capsular polysaccharides, glycosaminoglycans, hyaluronic acid, alginates, dextrans, carbohydrate excipients, glycan-containing drug substances and polysaccharide–protein conjugates. Some products emerge through custom carbohydrate synthesis. Others require fermentation, enzymatic elongation or a hybrid route that crosses several technical disciplines.

A leading carbohydrate cdmo must therefore answer three questions continuously:

What molecular architecture defines the product?

Which manufacturing route can reproduce it?

Which analytical system can prove that every batch remains equivalent where function matters?

The following 23 requirements form a practical crash course for sponsors evaluating a carbohydrate CDMO. They cover the full span of carbohydrate manufacturing services, process development, glycoconjugate manufacturing, analytical characterisation and GMP manufacturing—highlighting the capabilities that separate a true specialist from a general supplier.

A brief history: when sugars became structural information

Early carbohydrate chemistry established that sugars were not merely sources of energy. Their stereochemistry and arrangement carried biological information.

In 1929, Oswald Avery and Walther Goebel demonstrated that synthetic carbohydrate groups attached to proteins could create carbohydrate-specific immunological recognition. Their work showed that the sugar component could determine antigenic specificity even when attached to different proteins. That principle became foundational to modern glycoconjugate science.

Later conjugate-vaccine development transformed poorly immunogenic polysaccharides into more effective antigens by covalently linking them to carrier proteins. Modern pneumococcal, meningococcal, Haemophilus influenzae type b and typhoid conjugate vaccines now require controlled production of the polysaccharide, carrier and final conjugate as related but analytically distinct materials. WHO and FDA guidance reflect the resulting emphasis on molecular identity, free saccharide, molecular size, carrier quality, conjugation consistency, potency and stability.

The history reveals the central manufacturing principle: monosaccharide composition alone does not define a carbohydrate product. Architecture creates function.

1. Define the intended product before process development begins

The programme must first establish what the material is intended to become.

A discrete oligosaccharide, heterogeneous polysaccharide, glycosaminoglycan, conjugate-vaccine antigen, diagnostic reagent and pharmaceutical excipient do not share one quality profile. Their acceptable molecular distributions, purity requirements, biological tests and regulatory pathways differ substantially.

The target product profile should define:

• intended use and route;
• molecular composition;
• critical linkages and substitutions;
• molecular-size range;
• purity and impurity limits;
• biological or immunological function;
• required concentration;
• formulation;
• stability target;
• clinical or commercial stage.

A competent carbohydrate cdmo converts those needs into critical quality attributes before it starts optimising titre, yield or reaction conversion. Otherwise, a technically efficient process may manufacture the wrong molecular population.

2. Select the right manufacturing route

Carbohydrates can arise through chemical synthesis, enzymatic synthesis, microbial fermentation, extraction from biological material or combinations of those routes.

Chemical synthesis can provide exceptional structural control for selected oligosaccharides, but protecting-group strategy, stereoselectivity, cumulative yield and purification become harder as complexity increases.

Enzymatic routes can deliver strong regioselectivity and stereoselectivity under comparatively mild conditions. Their feasibility depends on enzyme availability, substrate scope, activated sugar donors, enzyme productivity and downstream removal.

Fermentation can generate high-molecular-weight polysaccharides economically, but strain biology, medium composition, culture conditions and recovery all influence the final distribution.

A hybrid process may ferment a precursor, depolymerise it, activate selected groups and then attach it to a carrier protein. Another may synthesise a core chemically before enzymatic extension.

The best route is not the most fashionable route. It is the one that balances structural control, scalability, impurity risk, cost, supply security and regulatory suitability.

Manufacturing-route comparison

Route	Principal strength	Central limitations	Typical fit
Chemical synthesis	Precise control of defined structures	Protecting groups, stereochemistry, cumulative yield	Short and medium defined oligosaccharides
Enzymatic synthesis	High regioselectivity and stereoselectivity	Enzyme and donor availability	Selective elongation and glycan modification
Fermentation	Efficient production of larger polymers	Biological variability and complex recovery	Capsular polysaccharides, hyaluronic acid, dextran, alginate
Biological extraction	Access to naturally produced materials	Source variability, contaminants, traceability	Selected glycosaminoglycans and natural polymers
Hybrid manufacture	Combines scale with structural refinement	More handoffs and broader analytical burden	Glycoconjugates and specialised complex glycans

3. Establish structural definition before selecting specifications

The structure must be defined at the level required by function.

For one product, monosaccharide identity and molecular weight may provide sufficient initial control. Another may require linkage analysis, anomeric assignment, branching frequency, degree of acetylation, sulphation pattern, reducing-end identity and three-dimensional conformation.

The analytical target should distinguish the intended product from structurally close variants that simpler methods could misclassify as equivalent.

A capsular polysaccharide may require serotype-specific identity and control of labile substitutions. A glycosaminoglycan may depend on sulphation position. Hyaluronic acid may depend heavily on molecular-weight distribution. A synthetic oligosaccharide may treat the wrong anomer as a distinct process impurity.

FDA and WHO guidance for conjugate vaccines similarly require characterisation of the polysaccharide, carrier and final conjugate rather than reliance on one bulk identity test.

4. Control anomeric configuration and linkage specificity

Two glycans can contain the same monosaccharides in the same proportions and still represent different molecules.

An alpha linkage and beta linkage can create different shapes, enzyme sensitivities and biological recognition. Changing a 1→3 linkage to 1→4 alters the product’s topology even when composition remains unchanged.

Custom carbohydrate synthesis must therefore control where each glycosidic bond forms and which anomer emerges. Donor design, protecting groups, leaving groups, promoters, solvents, temperature and neighbouring-group participation can influence selectivity.

Analytical release cannot depend solely on a chromatographic peak with the expected retention time. NMR, mass spectrometry, enzymatic digestion or other orthogonal methods may be needed to confirm the desired connection.

The chemistry must approach the intended hydroxyl group with almost intimate precision while leaving neighbouring sites undisturbed.

5. Develop defined oligosaccharide synthesis as a complete route

A successful laboratory reaction is not yet a manufacturable synthesis.

The complete route must address raw-material quality, intermediate isolation, reaction selectivity, cumulative yield, impurity fate, solvent use, hazardous reagents, temperature control and scalable purification.

Protecting-group choices can simplify one reaction and complicate several later operations. A promoter that performs well at milligram scale may create unacceptable safety or mixing problems at kilogram scale. Repeated chromatography may produce beautiful material but destroy commercial economics.

Route scouting should compare several pathways early. The team should examine telescoped operations, crystallisation, selective precipitation, membrane processing and alternative activation strategies before accepting preparative chromatography as the default answer.

The process should prevent difficult impurities whenever possible. Purification should not act as a parachute deployed after the chemistry has already lost control.

6. Build chemoenzymatic and hybrid capability

Some carbohydrate structures sit beyond the efficient reach of pure chemical synthesis or single-platform fermentation. The most interesting targets often demand a deliberate combination of both.

A chemoenzymatic route may construct a defined core chemically, then deploy glycosyltransferases to extend it with high regio- and stereoselectivity.

Fermentation can generate a complex polysaccharide that is later fractionated, chemically activated, selectively modified, or conjugated. Enzymatic depolymerisation frequently yields cleaner, more controlled fragments than harsh chemical cleavage, preserving functional epitopes that acid or oxidative methods destroy.

Hybrid processes expand access to complex glycans, yet they multiply technical dependencies. Success requires tight control over:

• enzyme source, activity and lot-to-lot consistency
• donor-substrate quality and stoichiometry
• residual enzyme removal
• reaction equilibrium and side-product formation
• cofactor recycling and regeneration
• seamless consistency between biological and chemical unit operations

Each transition between technologies creates an analytical boundary. The programme must define exactly what enters the next step, which structural attributes may shift, and how the subsequent operation preserves the intended architecture. Without that discipline, a hybrid process becomes a series of disconnected improvements rather than a coherent manufacturing route.

A versatile polysaccharide CDMO therefore treats these interfaces as design opportunities rather than problems to be avoided. It refuses to force a molecule into a single platform simply because that platform is familiar. Instead, it builds the hybrid path that the structure itself requires—chemical precision where it is strongest, enzymatic selectivity where chemistry struggles, and fermentation scale where biology is most efficient—while keeping the full analytical thread intact from first intermediate to final product.

7. Control starting materials and biological provenance

Chemical and biological routes carry different source risks.

Synthetic manufacture may depend on protected monosaccharides, rare sugar donors, catalysts, enzymes or linkers with limited suppliers. Fermentation-derived products require well-characterised production strains, controlled seed banks, documented passage history and qualified media components.

For biological sources, the programme should address:

• organism identity;
• provenance;
• genetic and phenotypic stability;
• plasmid status where relevant;
• containment;
• seed-lot controls;
• source-associated contaminants;
• chain of custody.

WHO recommendations for conjugate vaccines place clear emphasis on controlled seed systems, culture conditions, harvests and testing of polysaccharide intermediates.

A process cannot claim reproducibility when its starting biology remains loosely defined.

8. Develop fermentation around polymer quality

Fermentation development should maximise usable carbohydrate rather than biomass alone.

Carbon source, nitrogen availability, pH, temperature, dissolved oxygen, redox potential, osmolarity, agitation, gas transfer and harvest timing can influence titre, molecular size, substitution and impurity burden.

Polysaccharide accumulation may also change broth rheology. Increasing viscosity can reduce mixing and gas transfer, creating gradients that alter cell physiology and polymer formation. A culture may keep producing total carbohydrate whilst shifting towards an undesirable molecular-weight distribution.

The process should therefore measure product attributes during development, not merely at final purification.

A strong carbohydrate cdmo links fermentation conditions to structural quality, recovery and downstream behaviour. The useful result is not the highest broth assay. It is the greatest amount of functionally acceptable polymer recovered per batch.

9. Manage molecular weight and polydispersity

Many polysaccharides exist as populations rather than discrete molecules.

Number-average molecular weight, weight-average molecular weight, dispersity, hydrodynamic radius and higher-order conformation can affect viscosity, filtration, clearance, immunogenicity, conjugation and biological function.

The process may control molecular size during biosynthesis or through later depolymerisation. Chemical hydrolysis, oxidation, enzymatic cleavage, sonication and mechanical processing can all alter the distribution, but each method may also change end groups or damage labile substitutions.

SEC-MALS, viscometry and orthogonal size methods can help define the population. The method must account for charge, non-ideal interactions and conformation.

Averages deserve caution. Two batches can share the same average molecular weight while possessing very different high- and low-molecular-weight tails. WHO guidance for conjugate vaccines similarly treats molecular size as an important polysaccharide and conjugate attribute.

10. Preserve branching, charge and labile substitutions

Acetyl, sulphate, phosphate, pyruvate, methyl and amino substitutions can determine charge, conformation, antigenicity and receptor interaction.

These groups may be vulnerable to pH, heat, oxidation, prolonged processing or storage. A purification step can improve bulk purity while quietly reducing the structural feature that carries function.

Branching requires equal attention. Materials with similar composition and molecular weight may differ in branch frequency or linkage position. Those changes can affect viscosity, enzyme susceptibility and biological recognition.

Development should identify which substitutions and branches constitute critical quality attributes, then track them across fermentation, extraction, activation, purification, sterile processing and stability.

Structure-preserving manufacture protects the quiet details that make the molecule biologically recognisable.

11. Design purification around carbohydrate behaviour

Carbohydrates do not behave like conventional proteins or small molecules.

Highly charged polymers may bind unpredictably to surfaces and resins. Large molecules can foul membranes. Viscous solutions resist mixing and mass transfer. Structurally related polymers may differ only slightly in charge or size.

Downstream operations may include precipitation, centrifugation, filtration, ultrafiltration, diafiltration, ion exchange, hydrophobic-interaction methods, selective digestion and chromatographic polishing.

The purification train should remove impurities without altering molecular weight, conformation, substitution or functional epitopes.

Process teams should also monitor recovery by molecular population. A step may retain total carbohydrate while selectively losing one size fraction, thereby changing the product.

The cleanest chromatogram does not automatically represent the most faithful product.

12. Control carbohydrate-specific impurities

Carbohydrate impurity profiles depend strongly on the manufacturing route.

Fermentation-derived materials may contain endotoxin, host-cell proteins, nucleic acids, media residues, pigments, lipids, cell-wall components and unrelated polymers.

Chemical routes may generate residual solvents, catalysts, reagents, protecting-group remnants, positional isomers, anomers, deletion sequences, partially deprotected intermediates and degraded sugars.

Hybrid processes carry both landscapes.

The control strategy should define where each impurity enters and which unit operation removes it. In-process analytics can prevent the final release test from becoming the first moment at which a clearance problem appears.

For parenteral bacterial products, endotoxin control should influence strain handling, harvest, clarification and purification from the beginning rather than appear as a late polishing exercise.

13. Use orthogonal carbohydrate analytics

One analytical method cannot fully describe a complex carbohydrate.

A robust platform may combine:

• NMR for linkage, configuration and substitution;
• high-resolution mass spectrometry for defined species and fragments;
• HPAEC-PAD for monosaccharide and oligosaccharide analysis;
• SEC-MALS for absolute molecular-weight information;
• linkage analysis;
• capillary electrophoresis;
• chromatography for free saccharide and residual reagents;
• spectroscopy;
• rheology;
• immunochemical or receptor-binding assays.

Each method sees a different layer of the molecule.

The analytical strategy should answer four questions: Is this the intended structure? What else is present? Has the process altered a meaningful attribute? Does the material still perform its intended function?

FDA, WHO and ICH frameworks support broad characterization, impurity control, potency testing and justified specifications for biological products and conjugates.

Carbohydrate analytical services should function as a connected evidence system, not a catalogue of instruments.

14. Establish integrated in-process and release testing

Development analytics, in-process controls, release methods and stability assays should speak the same scientific language.

Early structural methods may be too elaborate for routine release, but they should identify the attributes that simpler validated methods must control later. The program can then establish correlations between detailed characterization and practical release tests.

For example, deep NMR analysis may support the selection of a faster identity method. SEC-MALS may define molecular-weight behaviour that a qualified SEC method later monitors routinely. A detailed conjugate study may establish a relationship between saccharide loading, free saccharide and potency.

The analytical thread should run from first feasibility material through validation and commercial release.

Without that continuity, each development stage rediscovers the molecule under a different name.

15. Master activation chemistry and bioconjugation

Glycoconjugate manufacturing creates an entirely new molecular entity. A carbohydrate is deliberately attached to a carrier protein, peptide, lipid, nanoparticle or other functional partner, transforming two separate components into a single therapeutic or vaccine construct.

Common activation and conjugation strategies include:

• reductive amination
• carbodiimide chemistry
• hydrazide reactions
• spacer-mediated coupling
• click chemistry
• selective enzymatic methods

Each route carries distinct advantages and risks. The activation step must generate a sufficient number of reactive sites on the carbohydrate without triggering excessive depolymerisation, unwanted crosslinking or the destruction of critical epitopes. Once activated, the conjugation reaction itself must tightly control concentration, pH, stoichiometry, mixing intensity, reaction time and quenching conditions.

The carbohydrate and carrier meet inside a narrow molecular window. Too little contact produces incomplete loading and weak immunogenicity. Uncontrolled intimacy generates aggregates, broad size distributions and loss of functional architecture. Success lies in finding the precise degree of engagement that maximises loading while preserving both the carbohydrate epitopes and the carrier’s integrity.

Regulatory expectations reinforce this discipline. FDA guidance requires sponsors to describe the polysaccharide activation method, the nature of the carrier, the conjugation chemistry, the subsequent purification steps and the testing applied to the final polysaccharide–protein conjugate. A leading carbohydrate CDMO therefore treats activation and bioconjugation not as downstream add-ons, but as core process design decisions that determine the identity, potency and consistency of the finished product.

16. Control saccharide loading and conjugate distribution

Average saccharide-to-protein ratio provides useful information, but it does not describe the complete population.

Two batches can share the same average ratio while differing in unconjugated carrier, free saccharide, highly loaded species, lightly loaded material, aggregates and crosslinked networks.

The process should evaluate:

• conjugation efficiency;
• free saccharide;
• free carrier;
• molecular-size distribution;
• aggregate content;
• residual linker;
• residual activation reagents;
• lot-to-lot distribution;
• retained antigenicity or function.

The correct analytical strategy depends on whether the product is a vaccine, targeting conjugate, diagnostic reagent or another glycan-bearing construct.

Conjugation converts two starting materials into a third product with its own identity. Testing only the inputs cannot prove control of the output.

17. Control carrier-protein quality

Carrier proteins such as CRM197, tetanus-derived proteins and other engineered carriers require their own manufacturing and analytical strategies.

Expression host, purification history, oxidation, aggregation, accessible reactive residues and lot variation can influence conjugation. A supplier change may alter loading behaviour even when the carrier has the same nominal identity.

The program should define:

• carrier identity and purity;
• structural integrity;
• aggregation;
• residual host impurities;
• reactive-site availability;
• storage conditions;
• consistency between lots.

Random conjugation may remain appropriate for many products, but it creates a distribution that must remain reproducible. Site-selective methods can narrow that distribution while adding technical complexity.

Carrier substitution is not automatically a routine raw-material change. It may trigger substantial comparability work.

18. Demonstrate biological function and potency

Correct composition does not prove correct function.

A polysaccharide may retain its constituent sugars while losing conformation, substitution or molecular size required for biological recognition. A conjugate may achieve the target loading but present the carbohydrate poorly to the immune system.

Potency may involve:

• immunochemical identity;
• receptor binding;
• enzyme modulation;
• anticoagulant or anti-factor activity;
• cell-based function;
• antigenicity;
• immunological response;
• product-specific functional assays.

WHO recommendations for pneumococcal, meningococcal, Hib and typhoid conjugate vaccines connect manufacturing control with physicochemical characterization, immunological function and clinical or nonclinical evaluation.

A release assay should measure something biologically relevant rather than merely convenient.

19. Manage viscosity and concentration

High-molecular-weight carbohydrates can become difficult to mix, pump, filter, sample and fill as concentration increases.

Viscosity can alter mass transfer, membrane flux, heat exchange, chromatography and filling accuracy. Polymer solutions may also display non-Newtonian behaviour, making laboratory observations unreliable at manufacturing scale.

Development should evaluate:

• concentration-dependent viscosity;
• shear sensitivity;
• pump selection;
• tubing diameter;
• mixing time;
• membrane fouling;
• sampling representativeness;
• fill accuracy;
• temperature dependence.

A process may produce acceptable material yet fail commercially because the final solution cannot move predictably through the equipment.

The team must treat rheology as part of product and process design, not an inconvenient measurement near the end.

20. Address sterile filtration and aseptic fill-finish early

High viscosity and large molecular size can make sterile filtration difficult or impossible under practical conditions.

Filtration may reduce recovery, alter the molecular-weight distribution, foul rapidly or expose the product to damaging pressure and shear. A glycoconjugate may also aggregate at membrane interfaces.

The sterility strategy should therefore begin during process design. Depending on the product, it may involve sterile filtration of suitable intermediates, aseptic processing, controlled bioburden reduction, terminal sterilization only where scientifically justified, or combinations of those approaches.

Fill-finish development should consider mixing uniformity, hold time, temperature, dose accuracy, container compatibility and particulate control.

Final-product handling should not become a late gear change after the upstream process has already been locked.

21. Develop formulation and container closure together

Carbohydrates may hydrolyse, oxidise, deacetylate, depolymerise, precipitate or change conformation during storage. Glycoconjugates add protein-associated risks such as aggregation, oxidation and deamidation.

Formulation development should examine pH, buffer, ionic strength, stabilisers, surfactants where appropriate, concentration, freeze–thaw exposure and container interaction.

Lyophilisation may improve the stability of selected materials, but freezing and drying can change molecular associations or conjugate integrity. The cycle must preserve reconstitution, molecular size, free-saccharide levels and potency.

Container closure can influence moisture, extractables, adsorption and long-term stability. The product and package should therefore develop together rather than meet for the first time during registration batches.

WHO and ICH frameworks similarly place stability and justified specifications within the product-control strategy.

22. Map degradation pathways and build stability-indicating methods

A stability result should explain how the molecule changes, not merely report that an assay declined.

Relevant pathways can include:

• hydrolysis;
• deacetylation;
• oxidation;
• depolymerisation;
• epimerisation;
• aggregation;
• free-saccharide formation;
• linker cleavage;
• carrier degradation;
• precipitation;
• conformational rearrangement.

Forced-degradation studies can help identify meaningful pathways and establish whether analytical methods detect them. Real-time and accelerated programs should then track relevant changes under proposed storage and excursion conditions.

For conjugates, degradation of the glycan, carrier or linkage may create different consequences. The stability package should separate those mechanisms whenever practical.

Shelf life is the molecule’s accumulated memory of chemistry, manufacturing, formulation and time.

23. Integrate process understanding, GMP and commercial control

Late-stage success requires more than a strong development batch. The programme must identify which material attributes and process parameters drive critical quality attributes, then use risk assessment and designed experiments to map those relationships across reaction conditions, fermentation, mixing, activation, purification and formulation.

The control strategy should act like a gyroscope—absorbing disturbance while remaining oriented around the structural and functional attributes that matter. Scale-up, process validation, PPQ, cleaning validation, method validation, change control and comparability all flow from that understanding, guided by ICH Q5E and Q6B principles.

A carbohydrate CDMO must also confront commercial realities: supplier redundancy, carrier and enzyme availability, solvent recovery, membrane capacity, batch duration, release timelines, waste handling and cost per releasable unit.

The final deliverable is not simply material. It is a transferable, controlled manufacturing system.

What sponsors should provide

A useful technical package allows a carbohydrate cdmo to evaluate fit and propose the smallest programme capable of resolving the most important risks.

Sponsors should provide:

• proposed structure or repeating unit;
• intended use and route;
• target molecular size;
• critical substitutions;
• prior synthesis or fermentation data;
• known impurity profile;
• available analytical methods;
• potency concept;
• formulation target;
• stability information;
• required scale;
• quality grade;
• regulatory stage;
• expected timeline.

For conjugates, include carrier identity, activation chemistry, linker, target loading and existing immunological or functional data. For fermentation-derived materials, provide strain history, media, culture conditions, harvest point and recovery information.

Missing information is normal. The development partner should identify the uncertainty that carries the greatest downstream consequence.

Frequently asked questions

What does a carbohydrate cdmo do?

It develops, characterizes and manufactures defined glycans, oligosaccharides, polysaccharides, carbohydrate-containing drug substances and glycoconjugates. Work may include chemical synthesis, enzymatic synthesis, fermentation, purification, analytics, conjugation, formulation, GMP manufacturing and technology transfer.

How are complex carbohydrates manufactured?

They may be produced through chemical synthesis, enzymatic synthesis, fermentation, extraction or hybrid routes. The best method depends on the structure, required scale, purity, molecular distribution, cost and intended application.

What is the difference between an oligosaccharide and a polysaccharide?

An oligosaccharide contains a relatively small number of linked monosaccharide units and may be structurally discrete. A polysaccharide usually contains longer chains and often exists as a molecular-weight distribution rather than one exact molecular species.

Why is anomeric configuration important?

Alpha and beta glycosidic bonds can create different molecular shapes, biological recognition and enzyme susceptibility. A product containing the wrong anomer may possess the correct composition but the wrong function.

Which methods characterize carbohydrate structure?

Common techniques include NMR, high-resolution mass spectrometry, HPAEC-PAD, SEC-MALS, monosaccharide analysis, linkage analysis, capillary electrophoresis, chromatography and product-specific biological assays.

How are fermentation-derived polysaccharides purified?

Processes may use clarification, precipitation, filtration, ultrafiltration, diafiltration, ion exchange and selective polishing. The sequence must remove cellular and process impurities without damaging molecular size, substitution or conformation.

What is glycoconjugate manufacturing?

Glycoconjugate manufacturing links a carbohydrate to a protein, peptide, lipid, nanoparticle or other component. The process controls carbohydrate activation, conjugation efficiency, loading, free saccharide, free carrier, aggregation and retained function.

Why is free saccharide important in conjugate products?

Free saccharide may indicate incomplete conjugation or degradation. Excessive levels can change product consistency and may not contribute the intended carrier-linked biological effect.

Can large polysaccharides be sterile filtered?

Some can, but high molecular weight and viscosity may cause membrane fouling, poor recovery or changes in molecular distribution. The sterility strategy should be evaluated early and may require aseptic processing rather than reliance on final filtration alone.

How is carbohydrate process comparability demonstrated?

Comparability uses structural, physicochemical, impurity, functional and stability data to assess whether a manufacturing change altered meaningful product attributes. The exact package depends on the change and the product’s development stage.

Controlling the hidden architecture

A leading carbohydrate CDMO must control more than yield. It must master stereochemistry, linkage, branching, substitution, molecular-weight distribution, synthesis or fermentation, purification, conjugation, viscosity, formulation and stability.

The strongest model starts with the structure that creates function. It then selects the right route, applies orthogonal analytics, links process parameters to critical quality attributes, and builds a release strategy that detects meaningful change.

Carbohydrates look repetitive on paper. In practice, a single linkage or substitution can redefine the product. The right partner makes those differences visible, controllable and transferable—from molecular architecture to reliable commercial supply.

Selected references

1. Avery OT, Goebel WF. Immunological specificity of synthetic sugar-protein antigens. Journal of Experimental Medicine, 1929.
2. World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, TRS 977, Annex 3.
3. World Health Organization. Recommendations for the production and control of meningococcal group C conjugate vaccines, TRS 924, Annex 2.

Learn more about our –> Carbohydrate CDMO Services

Email our team at info@elisebiopharma.com